-
Recent advancements in cancer treatment include OneCell Diagnostics' blood-based biopsy technology and research on using genetically modified salmonella to combat bowel cancer. These innovations aim to improve diagnosis and treatment outcomes for cancer patients, addressing significant health challenges globally.
-
Novo Nordisk's semaglutide, marketed as Ozempic and Wegovy, is poised to become the top-selling drug franchise globally. However, competition from Eli Lilly's Zepbound and other emerging treatments could challenge its dominance. Meanwhile, Smoothie King has launched a new menu catering to users of GLP-1 medications, reflecting the growing popularity of these drugs among Americans.
-
The weight-loss drug market is evolving with new entrants like Wegovy and Mounjaro gaining traction. Novo Nordisk's Wegovy is now available in China, while Eli Lilly's Mounjaro has been approved in Hong Kong. The competition intensifies as biotech firms develop innovative treatments amid rising demand for obesity management.